Page last updated: 2024-10-29

staurosporine aglycone and Temporomandibular Joint Disorders

staurosporine aglycone has been researched along with Temporomandibular Joint Disorders in 1 studies

staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor

Temporomandibular Joint Disorders: A variety of conditions affecting the anatomic and functional characteristics of the temporomandibular joint. Factors contributing to the complexity of temporomandibular diseases are its relation to dentition and mastication and the symptomatic effects in other areas which account for referred pain to the joint and the difficulties in applying traditional diagnostic procedures to temporomandibular joint pathology where tissue is rarely obtained and x-rays are often inadequate or nonspecific. Common diseases are developmental abnormalities, trauma, subluxation, luxation, arthritis, and neoplasia. (From Thoma's Oral Pathology, 6th ed, pp577-600)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Pelegrini-da-Silva, A1
Oliveira, MC1
Parada, CA1
Tambeli, CH1

Other Studies

1 other study available for staurosporine aglycone and Temporomandibular Joint Disorders

ArticleYear
Nerve growth factor acts with the beta2-adrenoceptor to induce spontaneous nociceptive behavior during temporomandibular joint inflammatory hyperalgesia.
    Life sciences, 2008, Dec-05, Volume: 83, Issue:23-24

    Topics: Adrenergic beta-2 Receptor Antagonists; Animals; Behavior, Animal; Carbazoles; Enzyme Inhibitors; Ep

2008